Krystal Biotech Stock Soars on Exceptional Quarterly Performance

Krystal Biotech has delivered a stunning quarterly report that significantly surpassed market projections, demonstrating both robust commercial execution and strategic global positioning. The company’s flagship gene therapy, VYJUVEK, continues to drive record financial results while international expansion initiatives gain momentum.

The third quarter of 2025 proved transformative for Krystal Biotech, with VYJUVEK generating net product revenue of $97.8 million. This figure substantially exceeded analyst expectations of $93.19 million, highlighting stronger-than-anticipated commercial performance.

Profitability metrics were equally impressive, with non-GAAP earnings per share reaching $2.66. This represents a tripling of net income to $79.4 million, dramatically outpacing the projected range of $1.03 to $1.12 per share. The company’s operational excellence is further evidenced by an extraordinary gross Read more...